Related Experiment Video
Updated: Aug 31, 2025

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Curcumin and its nano-formulations: Defining triple-negative breast cancer targets through network pharmacology,
Zhicheng Deng1,2, Guanghui Chen1, Yonghui Shi1
1Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Abstract:
Background: Curcumin (CUR) displays the capability of suppressing the proliferation and metastasis of various cancer cells. However, the effects and underline mechanisms of CUR to treat triple-negative breast cancer (TNBC) have not been systematically elucidated with an appropriate method. Methods: In the present research, a combination method of network pharmacology, molecular docking, and in vitro bio-experiment was used to investigate the pharmacological actions and underline mechanisms of CUR against TNBC. First, common targets of CUR and TNBC were screened via Venny 2.1.0 after potential CUR-related targets and targets of TNBC were got from several public databases. Then, the Gene Ontology (GO) function and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment were performed on the Metascape website, and the network of compound-targets-pathways was constructed via Cytoscape software. Moreover, the network of protein-protein interaction was constructed by the STRING database to screen potential targets. Moreover, molecular docking was applied to affirm the interaction of CUR with the screened top 10 potential targets. Finally, in vitro experiments were used to further verify the effects and mechanisms of CUR and its nano-formulation (CUR-NPs) against TNBC. Results: Forty potential targets of CUR against TNBC were obtained. STAT3, AKT1, TNF, PTGS2, MMP9, EGFR, PPARG, NFE2L2, EP300, and GSK3B were identified as the top 10 targets of CUR against TNBC. In vitro experiment verified that CUR and CUR-NPs could not only restrain the invasion, migration, and proliferation of MDA-MB-231 cells but also induce their apoptosis. In addition, molecular docking demonstrated that CUR could bind spontaneously with the screened top 10 targeted proteins, and a real-time PCR experiment demonstrated that both CUR and CUR-NPs could downregulate the genetic expression levels of the 10 targets. Moreover, according to the CUR-targets-pathways network, PI3K-Akt, EGFR tyrosine kinase inhibitor resistance, JAK-STAT, Foxo, and HIF-1 signaling pathways were identified as the important pathways of CUR effects on TNBC. Among them, the inhibiting effects of CUR and CUR-NPs on the JAK-STAT signaling pathway were further verified by the western blot analysis. Conclusion: Taken together, the present research demonstrates that CUR and CUR-NPs have pharmacological effects against TNBC via a multi-target and multi-pathway manner.
Insights
Curcumin (CUR) and its nano-formulation (CUR-NPs) show promise in treating triple-negative breast cancer (TNBC) by inhibiting multiple targets and pathways. This study elucidates CUR
Area of Science:
- Pharmacology
- Oncology
- Biochemistry
Background:
- Curcumin (CUR) exhibits anti-cancer properties, but its mechanisms against triple-negative breast cancer (TNBC) require detailed investigation.
- Triple-negative breast cancer (TNBC) remains a challenging subtype with limited targeted therapies.
Purpose of the Study:
- To elucidate the pharmacological actions and underlying mechanisms of Curcumin (CUR) against triple-negative breast cancer (TNBC) using a multi-modal approach.
- To evaluate the efficacy of Curcumin (CUR) and its nano-formulation (CUR-NPs) against TNBC cells.
Main Methods:
- A combination of network pharmacology, molecular docking, and in vitro bio-experiments was employed.
- Target identification involved public databases, Venn diagrams, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment.
- Protein-protein interaction networks, molecular docking, and in vitro assays (cell proliferation, migration, invasion, apoptosis, real-time PCR, Western blot) were utilized.
Main Results:
- Forty potential targets for CUR against TNBC were identified, with STAT3, AKT1, and TNF among the top 10.
- Curcumin (CUR) and CUR-NPs demonstrated significant inhibition of MDA-MB-231 cell proliferation, migration, and invasion, while inducing apoptosis.
- Molecular docking confirmed CUR's binding affinity to top targets, and experiments showed downregulation of target gene expression and inhibition of the JAK-STAT pathway.
Conclusions:
- Curcumin (CUR) and its nano-formulation (CUR-NPs) possess significant pharmacological effects against triple-negative breast cancer (TNBC).
- These effects are mediated through a multi-target and multi-pathway mechanism, including the JAK-STAT signaling pathway.
- The findings support the potential of CUR and CUR-NPs as therapeutic agents for TNBC.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Stabilize Microtubules

